Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
Study Details
Study Description
Brief Summary
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Participants with Early Manifest Stage I or II HD No study drug was administered in this study |
Other: No Study Drug was Administered in this Study
No study drug was administered in this study
|
Outcome Measures
Primary Outcome Measures
- Change from Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test, and IS [Baseline to 15 months]
cUHDRS = composite Unified Huntington's Disease Rating Scale TFC = Total Functional Capacity Scale TMS = Total Motor Scale SDMT = Symbol Digit Modalities Test SWR = Stroop Word Reading IS = Independence Scale
- Change from Baseline in Biomarkers of Neuronal Injury (e.g., CSF NfL and tau) at 3, 9, and 15 Months [Baseline to 15 Months]
CSF = Cerebrospinal Fluid NfL = Neurofilament Light Chain
- Change from Baseline in Brain Atrophy Endpoints (e.g., Whole Brain Volume Decline, Caudate Volume Decline) as Determined by Brain MRI, at 3, 9, and 15 Months [Baseline to 15 Months]
Secondary Outcome Measures
- Within-Participant Change from Baseline in CSF mHTT Levels at 3, 9, and 15 Months [Baseline to 15 Months]
mHTT=Mutant Huntingtin Protein
- Association of Change from Baseline in Clinical Measures (cUHDRS, TFC, TMS, SDMT, SWR, and IS) at 3, 9, and 15 Months [Baseline to 15 Months]
- Association of Change from Baseline in Biomarkers of Neuronal Injury (e.g., CSF NfL and tau) at 3, 9, and 15 Months [Baseline to 15 Months]
- Association of Change from Baseline in Brain Atrophy Endpoints, as Determined by Brain MRI at 3, 9, and 15 Months [Baseline to 15 Months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Capacity to consent to participate in the study as assessed using the Evaluation to Sign Consent tool and investigator judgment
-
Age 25 to 65 years, inclusive, at the time of signing Informed Consent Form
-
Early manifest, Stage I or Stage II HD (defined as TFC of 7-13, inclusive)
-
Genetically confirmed disease (CAG repeat length ≥ 36 in huntingtin gene by direct DNA testing)
-
Body mass index ≥18 and ≤32 kg/m2; total body weight >50 kg
-
Ability to undergo and tolerate MRI scans
-
Ability to tolerate blood draws and lumbar puncture
-
Ability and willingness to comply with all aspects of the protocol, including completion of interviews and questionnaires and carrying/wearing of a digital monitoring device
-
Stable medical, psychiatric, and neurological status for at least 12 weeks prior to screening and at the time of enrollment
-
Signed study companion consent for participation, if a study companion is available
-
For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods during the observational period
Exclusion Criteria:
-
Any condition, including severe chorea, that would prevent either writing or performing pen and paper or smartphone-based tasks
-
History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that required hospital visit and/or change in level of care within 12 months prior to screening
-
Current active psychosis, confusional state, or violent behavior
-
Any serious medical condition or clinically significant laboratory, vital sign, or electrocardiogram abnormalities at screening that, in the investigator's judgement, precludes the participant's safe participation in and completion of the study
-
Pregnant or breastfeeding, or intending to become pregnant during the study
-
Positive for hepatitis C virus antibody or hepatitis B surface antigen at screening
-
Known HIV infection
-
Current or previous use of an antisense oligonucleotide (including small interfering RNA)
-
Current use of antipsychotics prescribed for psychosis, cholinesterase inhibitors, memantine, amantadine, or riluzole including use within 12 weeks of enrollment
-
Treatment with an investigational drug within 30 days prior to screening or 5 half-lives of the investigational drug, whichever is longer
-
Antiplatelet or anticoagulant therapy within the 14 days prior to screening or anticipated use during the study, including, but not limited, to aspirin (unless ≤81mg/day), clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban, and apixaban
-
History of bleeding diathesis or coagulopathy; platelet count < lower limit of normal unless stable and assessed by the Investigator and Sponsor Medical Monitor to be not clinically significant
-
Malignancy within 5 years prior to screening, except basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated
-
History of gene therapy or cell transplantation or any other experimental brain surgery
-
Concurrent or planned concurrent participation in any clinical study without approval of the Medical Monitor
-
Presence of implanted shunt for the drainage of CSF or an implanted CNS catheter
-
Pre-existing structural brain lesion as assessed by MRI scan
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rocky Mountain Movement Disorders Center | Englewood | Colorado | United States | 80113 |
| 2 | Georgetown University; Research Division, Psychiatry | Washington | District of Columbia | United States | 20007 |
| 3 | Hereditary Neurological Disease Centre (HNDC) | Wichita | Kansas | United States | 67226 |
| 4 | John Hopkins University School of Medicine | Baltimore | Maryland | United States | 21287 |
| 5 | Columbia University | New York | New York | United States | 10032-3725 |
| 6 | The University of Texas Health Science Center at Houston; McGovern Medical School | Houston | Texas | United States | 77030 |
| 7 | The University of British Columbia; The Centre for Huntington Disease | Vancouver | British Columbia | Canada | V6T 2B5 |
| 8 | Centre for Movement Disorders (Neuropharm Consulting Inc.) | Markham | Ontario | Canada | L6B 1C9 |
| 9 | Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi | Berlin | Germany | 10117 | |
| 10 | St. Josef and St. Elisabeth gGmbH ; St. Josef Hospital Bochum; Neurologisches Forschungszentrum | Bochum | Germany | 44791 | |
| 11 | Universitätsklinikum Ulm; Klinik für Neurologie | Ulm | Germany | 89081 | |
| 12 | NIHR Welcome Trust Birmingham CRF - University Hospitals Birmingham; Department of Neuropsychiatry | Birmingham | United Kingdom | B15 2FG | |
| 13 | Cardiff University School of Medicine; Institute of Psychological Medicine Clinical Neurosciences | Cardiff | United Kingdom | CF24 4HQ | |
| 14 | National Hospital For Neurology and Neurosurgery | London | United Kingdom | WC1N 3BG | |
| 15 | Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine | Manchester | United Kingdom | M13 9WL |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BN40422